Abbott Q4 2020 Earnings Report
Key Takeaways
Abbott's Q4 2020 results showed strong growth, with worldwide sales increasing by 28.7 percent on a reported basis and 28.4 percent on an organic basis. The company achieved double-digit EPS growth and is forecasting EPS growth of more than 35 percent in 2021.
Worldwide sales increased 28.7 percent on a reported basis and 28.4 percent on an organic basis.
Diagnostics sales increased 111.1 percent on a reported basis, driven by demand for COVID-19 diagnostics tests.
Medical Devices sales increased 1.7 percent on a reported basis, with strong growth in Diabetes Care led by FreeStyle Libre.
The board of directors of Abbott increased the company's quarterly dividend to $0.45 per share, an increase of 25 percent.
Abbott
Abbott
Forward Guidance
Abbott projects full-year 2021 diluted earnings per share from continuing operations under GAAP of at least $3.74. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $5.00 for full-year 2021.